Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Olema Pharmaceuticals, Inc. (OLMA : NSDQ)

• Company Description    Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California. Number of Employees: 74

• Price / Volume Information    Yesterday's Closing Price: $2.26 Daily Weekly Monthly 20 Day Moving Average: 340,231 shares Shares Outstanding: 40.35 (millions) Market Capitalization: $91.20 (millions) Beta: 2.54 52 Week High: $32.77 52 Week Low: $2.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.65% -14.01% 12 Week -49.21% -44.17% Year To Date -75.85% -69.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 512 2nd Street 4th Floor - San Francisco,CA 94107 USA ph: 650-243-5555 fax: - ir@olema.com http://www.olema.com

• General Corporate Information    Officers Sean Bohen - President and Chief Executive Officer Shane Kovacs - Chief Operating and Financial Officer Ian Clark - Director Cynthia Butitta - Director Cyrus L. Harmon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68062P106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 40.35 Most Recent Split Date: (:1) Beta: 2.54 Market Capitalization: $91.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.87 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -48.72% vs. Previous Quarter: -7.41% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -27.06 12/31/21 - -23.20 09/30/21 - -18.63 ROA 03/31/22 - -26.15 12/31/21 - -22.58 09/30/21 - -18.25 Current Ratio 03/31/22 - 26.58 12/31/21 - 32.23 09/30/21 - 34.63 Quick Ratio 03/31/22 - 26.57 12/31/21 - 32.23 09/30/21 - 34.63 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 6.57 12/31/21 - 7.06 09/30/21 - 7.61 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©